383-19-7

Basic information

• Product Name: 2,2-DIFLUORO-2-PHENYLACETAMIDE
• Synonyms: 2,2-DIFLUORO-2-PHENYLACETAMIDE;2,2-Difluoro-2-phenylacetamide 97%;2,2-Difluoro-2-phenylacetamide97%;2,2-difluoro-2-phenyl-ethanamide
• CAS NO: 383-19-7
• Molecular Formula: C₈H₇F₂NO
• Molecular Weight: 171.14
• Mol File: 383-19-7.mol
• Article Data: 8

Chemical Properties

• Melting Point: 114-115
• Boiling Point: 317°Cat760mmHg
• Flash Point: 145.5°C
• Appearance: /
• Density: 1.269g/cm³
• Vapor Pressure: 0.000395mmHg at 25°C
• Refractive Index: 1.494
• CAS DataBase Reference: 2,2-DIFLUORO-2-PHENYLACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-DIFLUORO-2-PHENYLACETAMIDE(383-19-7)
• EPA Substance Registry System: 2,2-DIFLUORO-2-PHENYLACETAMIDE(383-19-7)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 383-19-7(Hazardous Substances Data)

Usage

General Description

2,2-Difluoro-2-phenylacetamide is a chemical compound with the formula C8H7F2NO. It is categorized under the class of organofluorides, mainly involving organic compounds that contain a carbon to fluorine covalent bond. This chemical is often used in the field of synthetic organic chemistry. It involves a fluorine atom, which makes the compound highly reactive and often used as a building block for creating more complex organic materials. It is characterized by its high stability and strong carbon-fluorine bonds. Moreover, the phenyl group present in 2,2-Difluoro-2-phenylacetamide gives the molecule aromatic characteristics, increasing its reactivity as well.

InChI:InChI=1/C8H7F2NO/c9-8(10,7(11)12)6-4-2-1-3-5-6/h1-5H,(H2,11,12)

Upstream product

• 2002-72-4 α,α-difluorobenzeneacetonitrile 
• 1603-79-8 phenylglyoxylic acid ethyl ester 
• 40626-45-7 α,α-dichlorobenzylcyanide 
• 2169-67-7 2-bromo-2,2-difluoroacetamide 
• 28557-00-8 phenylzinc chloride 
• 591-50-4 iodobenzene 

Downstream Products

• 360-03-2 2,2-Difluoro-2-phenylacetic acid 
• 2002-72-4 α,α-difluorobenzeneacetonitrile 
• 312-24-3 difluoro-phenyl-acetyl chloride 
• 402-03-9 (3-amino-phenyl)-difluoro-acetic acid 
• 2248-46-6 ethyl 2,2-difluoro-2-phenylacetate 
• 339-30-0 2,2-difluoro-N-2-diphenylacetamide 
• 650-93-1 2,2-difluoro-2-(3-nitrophenyl)acetic acid 
• 55601-21-3 2,2-difluoro-2-phenylethylamine 
• 885068-32-6 (6-chloro-2-methoxy-pyrimidin-4-yl)-(2,2-difluoro-2-phenyl-ethyl)-amine 
• 39625-10-0 2,2-difluoro-2-phenylethanamine hydrochloric acid salt 

Relevant articles and documents

Direct Approach to 3-Fluoroindoles and 3,3-Difluoroindolines from 2,2-Difluoro-2-phenylethan-1-amines via C-H/N-H Coupling

Herein, a direct method for the synthesis of 3-fluoroindoles and 3,3-difluoroindolines from easily accessible 2,2-difluoro-2-phenyl ethan-1-amines is presented. This protocol was performed by Pd-catalyzed direct C-H/N-H coupling and employed picolinamide as a directing group. By controlling the temperature for this transformation, various 3,3-difluoroindolines and 3-fluoroindoles could be isolated with moderate to good yields.

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.

2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).